Pan-cancer Analysis to Character the Clinicopathological and Genomic Features of KRAS-mutated Patients in China

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2025 Feb 27

PMID 40016583

Authors

Liyuan Wu

Wei Rao

Lei Guo

Fanshuang Zhang

Weihua Li

Jianming Ying

Affiliations

Soon will be listed here.

Abstract

Purpose: The Kirsten rat sarcoma viral oncogene (KRAS) is the most frequently mutated oncogene in human cancers. Significant advancements have been made in targeted therapy and immunotherapy for this gene in recent years, underscoring the importance of comprehensively understanding the genomic landscape of KRAS across various cancer types.

Methods: Using next-generation sequencing (NGS) technology and a panel of 520 genes, KRAS mutations, tumor mutation burden (TMB), and microsatellite instability (MSI-H) status were investigated.

Results: An analysis of 10,820 tumor samples found KRAS mutations in 19.97% of cases. Pancreatic cancer showed the highest prevalence of KRAS mutations at 73.51%, while colorectal at 41.45%, uterine at 21.23%, and lung cancer at 11.24%. KRAS G12D mutation is most common in pancreatic, colorectal, and gastric cancers, while KRAS G12V mutation is predominant in uterine cancer, and KRAS G12C mutation is most frequent in lung cancer. Significant correlations were found between TMB and KRAS G13D/G12V mutations in colorectal cancer. KRAS G13D notably affected TMB in uterus cancer, while KRAS G12C mutation was linked to high TMB in lung cancer. Moreover, statistical analysis revealed a significant association between KRAS G13D/G12V mutations and MSI-H in colorectal cancer.

Conclusions: KRAS mutations were most frequent in cancers of the digestive, female reproductive, and respiratory systems. Specific KRAS mutations are associated with TMB and MSI in various cancer types.

References

Herbst R, Garon E, Kim D, Cho B, Perez-Gracia J, Han J . Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study. J Clin Oncol. 2020; 38(14):1580-1590. DOI: 10.1200/JCO.19.02446. View

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

Hunter J, Manandhar A, Carrasco M, Gurbani D, Gondi S, Westover K . Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. Mol Cancer Res. 2015; 13(9):1325-35. DOI: 10.1158/1541-7786.MCR-15-0203. View

Chalmers Z, Connelly C, Fabrizio D, Gay L, Ali S, Ennis R . Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017; 9(1):34. PMC: 5395719. DOI: 10.1186/s13073-017-0424-2. View

Goldberg S, Redman M, Lilenbaum R, Politi K, Stinchcombe T, Horn L . Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of -Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403. J Clin Oncol. 2020; 38(34):4076-4085. PMC: 7768342. DOI: 10.1200/JCO.20.01149. View

Kemp S, Cheng N, Markosyan N, Sor R, Kim I, Hallin J . Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer. Cancer Discov. 2022; 13(2):298-311. PMC: 9900321. DOI: 10.1158/2159-8290.CD-22-1066. View

Kulkarni A, Kumar V, Parate S, Lee G, Yoon S, Lee K . Identification of New KRAS G12D Inhibitors through Computer-Aided Drug Discovery Methods. Int J Mol Sci. 2022; 23(3). PMC: 8836163. DOI: 10.3390/ijms23031309. View

McGranahan N, Furness A, Rosenthal R, Ramskov S, Lyngaa R, Saini S . Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016; 351(6280):1463-9. PMC: 4984254. DOI: 10.1126/science.aaf1490. View

Hargadon K, Johnson C, Williams C . Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018; 62:29-39. DOI: 10.1016/j.intimp.2018.06.001. View

Gao J, Aksoy B, Dogrusoz U, Dresdner G, Gross B, Sumer S . Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6(269):pl1. PMC: 4160307. DOI: 10.1126/scisignal.2004088. View

10.

Nakajima E, Drezner N, Li X, Mishra-Kalyani P, Liu Y, Zhao H . FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC. Clin Cancer Res. 2021; 28(8):1482-1486. PMC: 9012672. DOI: 10.1158/1078-0432.CCR-21-3074. View

11.

Dong Z, Zhong W, Zhang X, Su J, Xie Z, Liu S . Potential Predictive Value of and Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2017; 23(12):3012-3024. DOI: 10.1158/1078-0432.CCR-16-2554. View

12.

Sumimoto H, Takano A, Teramoto K, Daigo Y . RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers. PLoS One. 2016; 11(11):e0166626. PMC: 5112979. DOI: 10.1371/journal.pone.0166626. View

13.

Parvathaneni V, Chilamakuri R, Kulkarni N, Baig N, Agarwal S, Gupta V . Exploring Amodiaquine's Repurposing Potential in Breast Cancer Treatment-Assessment of In-Vitro Efficacy & Mechanism of Action. Int J Mol Sci. 2022; 23(19). PMC: 9569809. DOI: 10.3390/ijms231911455. View

13.

Cazzanelli G, Pereira F, Alves S, Francisco R, Azevedo L, Carvalho P . The Yeast Saccharomyces cerevisiae as a Model for Understanding RAS Proteins and their Role in Human Tumorigenesis. Cells. 2018; 7(2). PMC: 5850102. DOI: 10.3390/cells7020014. View

14.

Diaz Jr L, Shiu K, Kim T, Jensen B, Jensen L, Punt C . Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022; 23(5):659-670. PMC: 9533375. DOI: 10.1016/S1470-2045(22)00197-8. View

15.

Trabucco S, Gowen K, Maund S, Sanford E, Fabrizio D, Hall M . A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples. J Mol Diagn. 2019; 21(6):1053-1066. PMC: 7807551. DOI: 10.1016/j.jmoldx.2019.06.011. View

16.

Yoshino T, Andre T, Kim T, Yong W, Shiu K, Jensen B . Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer. Cancer Sci. 2022; 114(3):1026-1036. PMC: 9986093. DOI: 10.1111/cas.15650. View

17.

Amanam I, Mambetsariev I, Gupta R, Achuthan S, Wang Y, Pharaon R . Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival. J Thorac Dis. 2020; 12(9):5086-5095. PMC: 7578487. DOI: 10.21037/jtd.2020.04.18. View

18.

Hallin J, Bowcut V, Calinisan A, Briere D, Hargis L, Engstrom L . Anti-tumor efficacy of a potent and selective non-covalent KRAS inhibitor. Nat Med. 2022; 28(10):2171-2182. DOI: 10.1038/s41591-022-02007-7. View